| Name | Title | Contact Details |
|---|
IndiPharm is a Wayne, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
XpresSpa is the industry-leading luxury travel spa business and wholly owned subsidiary of XpresSpa Group Inc. (Nasdaq: XSPA). Serving almost one million air travelers each year at its 57 locations in the United States, Holland and the United Arab Emirates, including stores in 23 airports and 1 off-airport location at Westfield`s World Trade Center in New York City. XpresSpa offers travelers premium spa services, including massages, reflexology, stress and tension release, manicures, pedicures, facials and waxing. Its Xpres nail, massage and hair blow-out services are designed specifically for the busy traveling customer. In stores and online, XpresSpa also sells exclusive luxury travel products and accessories, including travel pillows, blankets, massagers, and personal, hair, nail and bath and body products. XpresSpa has over 750 employees, including talented teams of professionally licensed massage therapists, cosmetologists and nail technicians who are committed to providing exceptional customer experiences.
Pennington Apothecary is a full-service retail pharmacy located in the heart of downtown Pennington, NJ, offering personalized prescription service and well-being care.
Patient Comfort Systems is a Newark, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
DiagnoCure (TSX: CUR; OTCQX: DGCRF) is a life sciences corporation that develops and commercializes high-value cancer diagnostic tests that increase clinician and patient confidence in making critical treatment decisions. In 2008, the Corporation launched a colorectal cancer staging test through its U.S. CLIA laboratory. PrevistageTM GCC is currently available for licensing. The Corporation has granted a worldwide exclusive license on the diagnostic applications of its proprietary molecular biomarker PCA3 to Gen-Probe, now a wholly-owned subsidiary of Hologic Inc. Hologic Gen-Probe's PROGENSA® PCA3 prostate cancer test is commercialized in Europe under CE mark and is approved for commercialization in Canada and the United States.